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Meta-analysis is a vital tool in genetic epidemiology. However, meta-analyses to identify gene-disease associations are compromised
when contributing studies have typed partially overlapping sets of markers. Currently, only marginal analyses are possible, and these
are restricted to the subset of studies typing that marker. This does not allow full use of available data and leads to the confounding
of marker effects by closely associated markers. We present a Bayesian approach that exploits prior information on underlying haplo-
types to allow multi-marker analysis incorporating data from all relevant studies of a gene or region, irrespective of the markers typed.
We present results from application of our approach to data on a possible association between PDE4D and ischemic stroke.Introduction
The determination of the effect of genetic variation on
susceptibility to common human disease, or the effect of
genetic variation on the corresponding intermediate
phenotypes, is one of the key problems of modern biomed-
icine. However, it is now clear that genetic effects due to
common alleles are small and that detection requires both
comprehensive SNP screens and large sample sizes1–3:
manyprevious studieshavebeenunderpowered4,5, in terms
of sample size and/or in terms of using sets of genetic
markers that were not capable of representing unobserved
genetic variants with sufﬁcient accuracy. Recent genome-
wide association studies on large case-control collections
have partially overcome these difﬁculties and have been
highly successful in identifying genetic associations in
a number of diseases.6 However, synthesis of all available
evidence and data pooling remains important and, in the
case of several common diseases, has uncovered suscepti-
bility loci that individual studies couldnot identify reliably.7
It is often desirable to incorporate intometa-analyses the
results of prior gene-disease association studies fromwhich
only summary (rather than participant-level) data might
be available. The current study is motivated by the desire
to synthesize all available evidence regarding the putative
association between the gene encoding phosphodiesterase
4D (PDE4D [MIM 600129]) and ischemic stroke (MIM
#601367), ﬁrst reported in 2003.8 PDE4D encodes proteins
that degrade cAMP, a key signaling molecule that has
a range of vascular effects,9 and the biological plausibility
of PDE4D’s inﬂuencing stroke risk provided added interest
to this initial ﬁnding. However, a range of subsequent
studies have largely failed to replicate the initial ﬁnding.
A recent meta-analysis10 concluded that an effect of this
gene on stroke was unlikely; however, this meta-analysis
was restricted to single-SNP analyses of the six markersreported by ﬁve or more studies and therefore, as we see
below, does not incorporate much of the relevant data.
A key difﬁculty with attempting a more exhaustive
meta-analysis is that studies have typed partially overlap-
ping SNP sets so that many SNPs are unobserved in each
individual study; in fact, no SNP was present in all studies.
Moreover, studies report only summary data, typically
genotype or allele frequencies. The standard approach is
to pool all available data on each directly typed SNP in
turn. However, this is an inefﬁcient approach if our interest
is to detect an effect at a gene as a whole because data pool-
ing is only possible from a subset of studies that typed the
SNP in question. Univariate results are also difﬁcult to
interpret because they do not account for between-marker
association due to linkage disequilibrium (LD). When indi-
vidual patient data are available, imputating unobserved
SNPs and using the observed SNP data makes it possible
to incorporate data on all SNPs from all studies.11 However,
current imputation methods cannot work with summary
data and so are not applicable in this problem. We recently
developed a Bayesian method for meta-analysis that
accommodates summary SNP information from all studies
of the same gene or region irrespective of the SNPs typed.12
The method is applicable to continuous traits but not to
binary outcomes. Accordingly, we have now developed
a Bayesian hierarchical model that regresses a binary
outcome (e.g., disease: no disease) on summary data for
multiple SNPs, allowing the SNPs available to vary by
study. LD information on the set ofmarkers is incorporated
as prior information on haplotype frequencies, obtained
from HapMap or other sources. For each SNP, the method
provides effect estimates adjusted for the effect of all other
SNPs and allows a global test of the gene-disease associa-
tion. Although motivated by the association between
PDE4D and stroke, the approach is generic and potentially
widely applicable.1Center for Clinical Pharmacology, University College London, WC1E 6JJ London, UK; 2Department of Epidemiology and Population Health,
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Table 1. PDE4D SNP Sets Used by the Studies Analyzed
Studies by Bibliographic Reference
SNPa rs Number 27 28 29 25 30 14 26 23 24 31 32 10 8 13
2 rs152341 d
3 rs187481 d
5 rs27564 d
9 rs3117 d d d
13 rs26949 d
14 rs26950 d
15 rs35382 d
19 rs4133470 d
22 rs26954 d
26 rs40512 d d d d d
34 rs27653 d d d d
35 rs26955 d
37 rs26956 d
39 rs3887175 d
41 rs152312 d d d d d d d
42 rs153031 d d d d
45 rs12188950 d d d d d d d d d d d d d
48 rs37760 d
83 rs966221 d d d d d d d
87 rs2910829 d d d d d d
89 rs1396476 d d d d d
175 rs27171 d d
199 rs27547 d d
219 rs6450512 d
220 rs425384 d d
222 rs27727 d d d
Cases 89 94 97 151 222 248 250 259 376 639 685 737 988 1159
Controls 191 99 102 164 447 560 219 259 262 736 751 928 652 1564
a deCODE number.8Material and Methods
Systematic Review of PDE4D and Stroke
For their systematic review, Bevan et al.10 searched two electronic
databases (PubMed Medline and EMBASE) for literature published
from 1996 to October 1, 2007 by using the keywords ‘‘stroke,’’
‘‘SNP polymorphism,’’ ‘‘PDE4D,’’ and ‘‘phosphodiestrase 4D’’ in
isolation and combination with one another. The literature search
was limited to studies of humans. We obtained full texts of all the
identiﬁed articles to examine the association between PDE4D and
stroke in populations of European descent. We updated the litera-
ture search to August 12, 2008 but found no new relevant studies.
This current analysis incorporated 14 data sets from populations
of European descent, and a total of 12,929 subjects (5994 cases
and 6935 controls) and 33 SNPs were genotyped in at least one
study (Table S4 for study details). In the cases of Gretarsdottir8
and Kuhlenbaeumer,13 SNP data not included in the original publi-
cations were obtained from Brophy14 and Bevan10, respectively.
Because our method relies on prior information on LD from
HapMap, we restricted analysis to the 26 typed markers included
in HapMap. No SNP was typed in every study, but there was partial
overlap of SNP typing across several studies (see Table 1).
Bayesian Hierarchical Model
We model the single-locus counts of alleles in cases and controls
reported by each study. Our model is written in terms of a set of568 The American Journal of Human Genetics 84, 567–580, May 15underlying haplotype probabilities, and the case haplotype prob-
abilities differ from control probabilities via parameters that can
be interpreted as adjusted odds ratio (OR) values for each SNP.
Below we describe the form of the likelihood and sketch a number
of extensions, for instance allowing variation in the underlying
haplotype probabilities across studies. The model is ﬁtted in the
Bayesian framework via Markov chain Monte Carlo; accordingly,
we go on to describe the prior distributions and sampling scheme
used.
Likelihood
Consider M markers with H underlying haplotypes and S studies
reporting on some subset of the markers. Our data consist of the
marginal minor-allele counts in cases and controls reported by
each study at each marker. Take d ¼ 1 to indicate cases and d ¼ 0
to indicate controls, let qsd denote the marginal minor-allele
counts observed by study s; note that many of these qsd will
be unobserved. We can write these in terms of the (unobserved)
H 3 1 vector of counts of the underlying haplotypes,
hsd ¼ ðhsd,1,.hsd,H Þ’, by summing over the haplotypes that contain
the allele of interest; more formally, we deﬁne anM 3 Hmatrix D
where Dij is 1 if haplotype j carries the minor allele at locus i and
zero otherwise, so that
qsd ¼ Dhsd (1)
The haplotype counts are naturally assumed to have a multino-
mial distribution, hsd  Mnð2nsd,psdÞ, where psd ¼ ðpsd,1,::psd,H Þ0 are
the appropriate haplotype probabilities and nsd is the number of, 2009
cases/controls in study s. Note that the pair of haplotypes within
each person are assumed to be independent (i.e., Hardy-Weinberg
equilibrium is assumed). Observing that 2nsd, the sum of the haplo-
type counts, is ﬁxed by design in cases and controls, we may
reduce the number of free parameters needed to describe qsd by
one. Because hH ¼ 2nsd 
P
h¼1,::H1 hh, by conditioning on n
s
d we
may construct a mapping f : hs½Hd/q
s
d, where h
s
d½H indicate
the ﬁrst H – 1 haplotype counts only:
qsd ¼ fðhsd½HÞ ¼ DXhsd½H þ 2nsdD½,H, (2)
where D[, H] denotes the Hth column of D, and the H 3 H – 1
matrix X is
X ¼
2
66664
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We would like to use the above relationship between qsd and
hsd½H, together with the fact that the haplotype counts h
s
d have
a multinomial distribution, to calculate the likelihood of the allele
counts, Pðqsd jp,nsdÞ, but this is not straightforward. Instead, we
approximate the likelihood of the log-allele counts by a multivar-
iate normal distribution distribution, with mean and variance
written in terms of psd½H and n
s
d and derived via the multivariate
delta method, known to perform well for log-multinomial
counts.15 Via details given in Appendix A, we obtain:
logðqsdÞ jpsd½H,nsd
 MVN

log

f

2nsdp
s
d½H

,2nsd

vlogðqs
d
Þ
vqs
d
DX

Sðpsd½HÞ

vlogðqs
d
Þ
vqs
d
DX
0
,
(3)
where Sðpsd½HÞ is the multinomial covariance matrix of these ﬁrst
H – 1 haplotype probabilities. Note that where elements of
logðqsdÞjpsd½H,nsd are unobserved, for instance because a given
marker is not typed in study s, the appropriate likelihood is easily
obtained because the marginal distribution of any subset of the
components of a multivariate normal distribution is alsomultivar-
iate normal distribution, with amean and variance easily obtained
from the above. If we were interested solely in investigation of
whether haplotype frequencies differ between cases and controls,
we could work directly with the above model for logðqsdÞjpsd½H,nsd.
However, we also wish to investigate which SNPs might be associ-
ated with the disease. We therefore write the haplotype probabili-
ties in cases,ps1, in terms of the haplotype probabilities in controls,
ps0 and M adjusted SNP log-ORs, which we denote b ¼ ðb1,::bMÞ0.
We assume SNP ORs combine log additively across loci so that
the log-OR for a given haplotype is the sum of the log-ORs for
the component SNP, i.e., the haplotypic log-ORs are given by
bH ¼ D0b, where D is the design matrix deﬁned above. From16,
ps1,j ¼
ps0,jexp

bHj

P
i¼1,::H
ps0,iexp

bHi
 for j ¼ 1,H: (4)
Equation (3) may be used directly to obtain the likelihood
Pðqs0jps0½H,ns0Þ for controls. Substituting bH ¼ DTb into (4) and
the resulting expression for ps1½H (parameterized by p
s
0½H and
b) into (3) gives the independent likelihood, Pðqs1jps0½H,ns1,bÞ,
for cases. The full likelihood is then
P

qs0,q
s
1 jps0½H,ns0,b
 ¼ Pqs0 jps0½H,ns03Pqs1 jps0½H,ns1,b:The AmSo far we have worked with separate sets of haplotype frequen-
cies ps0 in each study. We expect these to be similar, but possibly
not identical, across studies and so model these hierarchically
via a multinomial logit link to a set of Gaussian random effects:
ps0,h ¼
exp

gsh

P
i¼1,::H
exp

gsi
 for h ¼ 1,::H and s ¼ 1,::S (5)
where
gsh  N

gh, sHap

for h ¼ 1, ::H and s ¼ 1, ::S: (6)
Note that sHap gives a measure of the heterogeneity in haplotype
frequencies across studies.
Model Fitting
We work within the Bayesian framework, so our objective is to
calculate the posterior distribution for the parameters of interest,
i.e., the probability distribution of those parameters given the
observed data. We also want to allow inference on which SNPs
affect the trait of interest, which we achieve by allowing some or
all of the SNP OR b values to be exactly zero. We use m to indicate
the model, that is, which SNPs are not zero, and so wish to calcu-
late
Pðps0,b,m jqsdÞfPðqsd jps0,bÞPðps0,b,mÞ:
We cannot calculate this analytically and so use Markov-chain
Monte Carlo, speciﬁcally reversible jump Metropolis-Hastings
(RJMH)17,18, to sample from the required posterior. The RJMH
sampling scheme starts at an initial model and set of parameter
values, m(0) and qð0Þ ¼ ðps0ð0Þ,bð0Þ,sð0ÞÞ. To sample the next
model and set of parameters, m(1) and q(1), we propose moving
from the current state to another model and/or set of parameter
values, m* and q*, by using a proposal function q(m*, q*jm, q).
We then accept these proposed values as the next sample with
probability equal to the Metropolis-Hastings ratio:
MHR ¼ Pðq
s
d jm,qÞPðm,qÞ
Pðqsd jm,qÞPðm,qÞ
3
qðm,q jm,qÞ
qðm,q jm,bÞ:
If this new set of values is accepted, the proposed set is accepted
as m(1) and q(1); otherwise, the sample value remains equal to the
current sample value, i.e., m(1) ¼ m(0) and q(1) ¼ q(0). It can be
shown that this produces a sequence of samples that converge
to the required posterior distribution.19 More details about the
scheme used are in Appendix B.
Bayes Factors
Increasingly, Bayes factors (BFs) are being used in genetic epidemi-
ology as an alternative to p values.6,20 A Bayes factor is deﬁned as
the posterior-to-prior odds of two competing models, that is,
model mi in comparison to model mj
BF

mi,mj
 ¼ Pðmi j DÞ
P

mj j D
=PðmiÞ
P

mj

where D denotes the data. BF(mi,mj) is a measure of howmuch our
prior beliefs about the relative merits of mi and mj change after
observing the data.
Priors
Priors for b and sHap are bm ~ N(0, 0.4) form ¼ 1, ..M and 1/s2Hap ~
Gamma[0.001, 0.001].
The prior for the log-ORs is realistically informative, suggesting
that most of the density for the ORs lies between 0.5 and 2.
Genetic ORs outside this range are rarely observed.3 If the causal
variant is unobserved, one would expect adjusted ORs at SNPs inerican Journal of Human Genetics 84, 567–580, May 15, 2009 569
positive LD to be in the same direction (and in opposite directions
if the LD is negative). This prior information could be reﬂected
with a multivariate normal covariance matrix for the log-ORs,
and we have implemented such a prior. However, this gave almost
identical results to the independent priors above, so for simplicity,
these are used here. A Gamma[0.001,0.001] prior for between-
study precision is a standard reference prior;21 alternative priors
give very similar results.
A vital part of our approach is the use of an informative prior
distribution for the haplotype frequencies p0: this enables the
model to share informationbetween associatedmarkers andobtain
adjusted estimates of SNP ORs. In the current work this has been
based on the 120 founding haplotypes from the HapMap trios of
European ancestry (see Web Resources). We have accordingly
assumed that p0  Dirichletð1203pHapMapÞ, where pHapMap denotes
the H haplotype frequency estimates in HapMap.
We also need to specify a prior on the model space, which we do
by specifying a prior on k SNPs in the model and then assuming
that all models with k SNPs are equally likely. This could of course
be modiﬁed where certain SNPs—perhaps because of prior
evidence of functionality—are judged more likely to be causal
than others.
We judged PDE4D to be a strong candidate gene for association
with stroke and so allowed a prior probability of 10% that one or
more SNP has a non-zero effect by using a truncated Poisson prior
with appropriate mean (Figure S1 in the Supplemental Data). We
also examined sensitivity to this prior.
Single-SNP Random-Effects Meta-Analysis
Where possible, we compared results from ourmulti-SNPmodel to
those obtained from an orthodox single-SNP random-effects meta-
analysis in both simulation studies and the PDE4D/stroke data set.
In both cases additive ORs were calculated for each study via
logistic regression. The study-speciﬁc estimates and their standard
errors were pooled via random-effect models. The DerSimonian
and Laird Q test, as well as the I222, were used for evaluating the
degree of heterogeneity between studies.
Results
Simulation Studies
For these simulations we examined the effect of alterations
in effect size (including no effect), the location and
number of causal sites, allele frequency of causal marker,
and whether the causal site was observed. Haplotypes for
ﬁve biallelic markers on the PDE4D gene were simulated
with a multinomial model, centered on HapMap-based
frequencies. The LD pattern for the ﬁve loci is given in
Figure 1. We partitioned multinomially drawn haplotypes
into cases and controls by assigning disease status with
a probability conditional on the presence of designated
causal SNP(s) via a logistic regression model with desired
causal SNP ORs. We then obtained marginal MAFs for
each SNP by summing over the relevant haplotype
frequencies. Data was simulated as though from 14 studies,
with case and control numbers approximately equal to the
14 PDE4D/stroke studies obtained in our literature review.
To model potential heterogeneity in LD structure
between different populations, we generated different570 The American Journal of Human Genetics 84, 567–580, May 15haplotype probabilities, ps for s ¼ 1,.14 and pPrior ; with
which to stimulate each study and to use as prior informa-
tion in our model, respectively. For each study a value was
drawn for each haplotype from a normal distribution with
a standard deviation of 0.1 centered on the corresponding
log-haplotype probability from HapMap. Multinomial-
logit transformations were then used for generating
study-speciﬁc haplotype probabilities that sum to one.
This means that the parameter sHap, which our model
uses to capture study heterogeneity in haplotype frequen-
cies, was set to 0.1 for the data simulation. For each
replicate an additional set of haplotype probabilities
was generated as above to act as prior information in
place of the underlying HapMap probabilities; therefore,
we also model possible heterogeneity between the
HapMap population and the populations in the published
studies.
Finally, to reﬂect the variation in SNP sets used by
different studies, we introduced missingness (the level of
missing data) in the same pattern as that observed in the
real studies for SNPs 41–83 (see Tables 1 and 2). For each
simulation scenario, 20 replicate data sets were generated
in the same way. When a single causal site was simulated,
single-SNP analysis produced signiﬁcant results at multiple
sites. Although the effect estimates were always largest and
closest to the truth at the causal SNP, for ORs of 1.5 and
above all other SNPs were signiﬁcant at the 5% level in
all replicated data sets. Therefore, univariate analysis of
these data would most likely conclude that all ﬁve markers
were possible causal sites. When the effect size was reduced
to 1.25, all other SNPs were signiﬁcant in between 65%
and 100% of replicates (Table 3). When two causal
sites were simulated, the univariate analysis substantially
underestimated the effect at both sites. Because the two
causal sites are in strong negative LD, the effect at each is
Figure 1. Pairwise LD between the Markers Used in the Simu-
lation Studies
Based on the r2 pairwise LD measure., 2009
Table 2. Information on Missingness in Simulated Data Sets
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5
Mean allele Frequency 0.37 0.43 0.44 0.44 0.46
Number of studiesa 7 4 13 1 7
Average casesb 6,058 3,178 11,488 1,976 6,214
Average controlsb 6,136 3,140 13,430 1,304 6,302
The same pattern of missingness was used in all scenarios for simulating each replicate data set. This is equivalent to the pattern of missingness for SNPs 42
to 83 in the real PDE4D data (see Table 1).
a In each replicate, this is the number of studies to have measured the marker (there are 14 studies in total).
b As a result of our simulation method, the number of cases and controls varies slightly in each replicate. However, these are the average numbers of cases
and controls providing data on each marker.confounded by the other, resulting in a bias toward the
null hypothesis (Table 4). This highlights an important
use of multiple-marker models: when there are multiple
causal sites, adjustment of between-marker confounding
may be essential for revealing an effect of the gene on
disease.
All Bayesian multi-SNP analyses use a truncated Poisson
(0.1) prior onmodel space, as described in theMaterial and
Methods, and were run for 20 million iterations. An anal-
ysis of one replicate for 20 million iterations takes around
2 hr to complete on a 2.5 GHz quad core desktop PC.
Marginal posterior probabilities of selecting each SNP are
presented. OR estimates are presented over all iterations
and are conditional on inclusion in the model; note that
when interpreting the latter, one must take care unless
posterior probability is high. Our model consistently
distinguished causal SNPs in all scenarios. When a single
site was simulated as causal, for effect sizes of 1.5 and above
the causal marker was selected with 100% posterior proba-
bility, whereas noncausal SNPs were given low posterior
probabilties (the highest in these anlyses was 7%). When
the effect size was reduced to 1.25, the causal site was still
selected with high posterior probabiltity (81%), and the
highest probability given to a noncausal marker was stillonly 14% (Table 5). Effect estimates were similar to the
simulated values at causal SNPs, regardless of the choice
of causal site. This remained true for multiple causal sites,
showing that, in contrast to single-SNP analysis, our model
successfully adjusts for most of the downward confound-
ing the two sites exert on one another (Table 6). To inves-
tigate the performance of themodel with SNPs of low allele
frequencies, we derived a new set of haplotype probabili-
ties for the multinomial generation model such that the
allele frequency at SNP 2 was reduced from 0.43 to 0.14.
On simulations based on these haplotype probabilities
and a causal OR of 1.5 at SNP 2, the model performed
equally well at adjusting for the between-marker con-
founding present in single-SNP analysis of the same data
(Tables S1 and S2).
We simulated a scenario in which the causal marker has
not been typed by deleting data on SNP 2 from the repli-
cates in which this SNP was simulated as causal with an
OR of 1.5. Prior haplotype probabilities in each replicate
were collapsed accordingly, and data on the remaining
four markers were analyzed by our model. This may be
compared to results from the standard univariate analysis
of the same data at noncausal sites (Table 3). In contrast
to the univariate analysis, our model successfully correctedTable 3. Average Results from Single-SNP Meta-Analyses of Simulated Data Replicates
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5
Number of studies 7 4 13 1 7
True OR 1 1.5 1 1 1
Proportion significanta 1.00 1.00 1.00 1.00 1.00
Mean OR (SE) 0.82(0.01) 1.51(0.02) 1.38(0.01) 1.39(0.02) 0.78(0.01)
Mean CI length 0.14 0.34 0.15 0.38 0.13
True OR 1 1.25 1 1 1
Proportion significanta 0.65 0.95 1.00 0.80 0.80
Mean OR (SE) 0.90(0.01) 1.26(0.02) 1.19(0.01) 1.2(0.02) 0.87(0.01)
Mean CI length 0.15 0.30 0.13 0.34 0.15
True OR 1 2 1 1 1
Proportion significanta 1.00 1.00 1.00 1.00 1.00
Mean OR (SE) 0.70(0.01) 2.03(0.02) 1.74(0.01) 1.76(0.03) 0.66(0.01)
Mean CI length 0.12 0.46 0.19 0.48 0.11
For each scenario results are means (SE) of the OR estimate over 20 analyses of replicate data sets simulated under identical conditions.
a Proportion of replicates in which the SNP is significant at the 5% level.
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Table 4. Average Results from Single-SNP Meta-Analyses of Simulated Data Replicates
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5
Number of studies 7 4 13 1 7
True OR 1 1 1 1 1.5
Proportion significanta 1.00 0.95 1.00 0.95 1.00
Mean OR (SE) 1.17(0.01) 0.79(0.01) 0.79(<0.01) 0.77(0.01) 1.50(0.01)
Mean CI length 0.19 0.18 0.09 0.21 0.25
True OR 1 1.5 1 1 1.5
Proportion significanta 0.15 0.75 0.90 0.15 0.95
Mean OR (SE) 0.96(0.01) 1.18(0.01) 1.09(<0.01) 1.08(0.02) 1.18(0.01)
Mean CI length 0.16 0.25 0.11 0.29 0.18
For each scenario results are means (SE) of the OR estimate over 20 analyses of replicate data sets simulated under identical conditions.
a Proportion of replicates in which the SNP is significant at the 5% level.for confounding at SNPs 1 and 5. Furthermore, our model
correctly inferred a single causal site, splitting the posterior
probability between SNPs 3 and 4, which both have
the strongest LD with the unobserved causal variant
(Table 7). Encouragingly, when no causal site was simu-
lated, average posterior probability over 200 replicates
was %0.03 at all SNPs, indicating that the false-positive
rates of our model are extremely low (Table S3).
A Meta-Analysis of the Association between PDE4D
and Stroke
To investigate heterogeneity inMAF estimates between the
studies, and between the studies and HapMap, we plotted
study-speciﬁcMAF estimates and 95% conﬁdence intervals572 The American Journal of Human Genetics 84, 567–580, May 15(CIs) for controls. This yielded concerns for SNPs 9 and 41
(Figure 2). The HapMap MAF for SNP 9 is substantially
different from that reported by the three studies in which
it was typed (p < 1033 for a test of equality of propor-
tions); because only Zee et al.23 report the rs number (as
rs3117), it seems possible this SNP might have been misi-
dentiﬁed. For SNP 41 the position is less clear, but the
SNP shows substantial heterogeneity (p ¼ 0.0041 for
a test of equality of proportions). HapMap MAF estimates
were not substantially different from those reported by
studies for any other SNP, although the SNP 45 MAF re-
ported by Meschia24 is noted as an outlier (Figures S2 and
S3). In addition, SNPs 42 and 48 are identical in
HapMap, meaning analysis of both SNPs simultaneouslyTable 5. Average Results from Bayesian Multi-SNP Meta-Analyses of Simulated Data Replicates
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5 sHap
Number of studies 7 4 13 1 7 –
True OR 1 1.5 1 1 1 –
Mean posterior probability (SE) 0.02(0.05) 0.99(0.05) 0.07(0.19) 0.05(0.09) 0.04(0.06) 1.00(0)
Mean OR (SE) 1.00(<0.01) 1.50(0.13) 0.99(0.06) 1.00(<0.01) 1.00(<0.01) 0.11(0.02)a
Mean BCI length 0.02 0.39 0.05 0.07 0.04 0.10
Mean OR present (SE)b 1.02(0.05) 1.50(0.13) 0.94(0.08) 0.97(0.13) 1.02(0.08) 0.11(0.02)a
Mean BCI length presentb 0.12 0.38 0.27 0.29 0.22 0.10
True OR 1 1.25 1 1 1 –
Mean posterior probability (SE) 0.02(0.03) 0.81(0.29) 0.14(0.18) 0.12(0.18) 0.04(0.08) 1.00(0)
Mean OR (SE) 1.00(<0.01) 1.22(0.12) 1.01(0.04) 1.01(0.04) 1.00(<0.01) 0.11(0.02)a
Mean BCI length 0.02 0.31 0.14 0.12 0.03 0.10
Mean OR present (SE)b 1.00(0.07) 1.26(0.08) 1.01(0.16) 1.00(0.14) 1.00(0.08) 0.11(0.02)a
Mean BCI length presentb 0.13 0.26 0.31 0.34 0.19 0.10
True OR 1 2 1 1 1 –
Mean posterior probability (SE) < 0.01(0.01) 1.00(<0.01) 0.03(0.05) 0.02(0.01) 0.03(0.02) 1.00(0)
Mean OR (SE) 1.00(<0.01) 1.98(0.05) 1.00(<0.01) 1.00(<0.01) 1.00(<0.01) 0.12(0.02)a
Mean BCI length < 0.01 0.33 0.04 0.02 0.03 0.10
Mean OR present (SE)b 1.02(0.04) 1.98(0.05) 0.97(0.08) 1.01(0.10) 1.02(0.08) 0.12(0.02)a
Mean BCI length presentb 0.12 0.33 0.25 0.32 0.24 0.10
For each scenario, results are means (SE) of estimators over 20 analyses of replicate data sets simulated under identical conditions. In each analysis, OR
estimates were taken as the median of the posterior sample.
a These are point estimates of sHap and therefore are not ORs.
b Calculated on the condition that the SNP was included in a model., 2009
Table 6. Average Results from Bayesian Multi-SNP Meta-Analyses of Simulated Data Replicates
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5 sHap
No. Studies 7 4 13 1 –
True OR 1 1 1 1 1.5 –
Mean posterior probability (SE) 0.03(0.04) 0.03(0.05) 0.01(<0.01) < 0.01(0.01) 1.00(<0.01) 1.00(0)
Mean OR (SE) 1.00(<0.01) 1.00(<0.01) 1.00(<0.01) 1.00(<0.01) 1.50(0.04) 0.12(0.02)a
Mean BCI length 0.02 0.03 < 0.01 < 0.01 0.18 0.10
Mean OR present (SE)b 1.00(0.05) 1.04(0.07) 1.03(0.03) 1.03(0.05) 1.50(0.04) 0.12(0.02)a
Mean BCI length presentb 0.14 0.22 0.18 0.14 0.18 0.10
True OR 1 1.5 1 1 1.5 –
Mean posterior probability (SE) 0.03(0.08) 0.95(0.22) 0.01(0.02) 0.08(0.25) 1.00(<0.01) 1.00(0)
Mean OR (SE) 1.00(<0.01) 1.51(0.18) 1.00(<0.01) 1.01(0.09) 1.52(0.1) 0.11(0.02)a
Mean BCI length 0.02 0.53 0.02 0.04 0.47 0.10
Mean OR present (SE)b 1.02(0.06) 1.52(0.16) 1.01(0.09) 1.00(0.12) 1.52(0.10) 0.11(0.02)a
Mean BCI length presentb 0.14 0.53 0.27 0.25 0.47 0.10
For each scenario, results are means (SE) of estimators over 20 analyses of replicate data sets simulated under identical conditions. In each analysis,
OR estimates were taken as the median of the posterior sample.
a These are point estimates of sHap and therefore are not ORs.
b Calculated on the condition that the SNP was included in a model.in our model is impossible because they would be identical
in the underlying HapMap-deﬁned haplotypes. Conse-
quently, SNP 48, which was typed in only one study,8
was excluded from our analysis.
Our analysis is thus based on 23 SNPs, which are divided
among three LD blocks: block 1, SNPs 2–37; block 2, SNPs
39–89; and block 3, SNPs 175–222 (Figure 3). Because
HapMap haplotype information is sparse over the
complete set of 23 markers but reasonable within each
LD block and indicates that there is very little LD between
the blocks, we analyze each block independently.
Tables 8, 9, and 10 present univariate meta-analysis of
the SNPs in the three blocks. No SNP was signiﬁcant at
the 5% level; the strongest evidence of association is at
SNPs 5, 175, 219, and 222, where 95% CIs just include 1
and moderately large effects are not excluded by the
data. Signiﬁcant p values from the DerSimonian and Laird
test of heterogeneity in reported effect estimates was found
at SNPs 42, 83, 87, and 89 (see Figure S4 for forest plots).
This was mostly explained by Gretarsdottir8 (whose effectThe Amestimate is in the oppposite direction of that proposed by
all other studies at SNP 42) and Staton25, who, unusually,
found signiﬁcant ORs for three of the six SNPs for which
they reported results.
Tables 11, 12, and 13 present results from our multi-SNP
analysis of blocks 1, 2, and 3, respectively. There is no
evidence for association: the posterior probability of non-
zero effect is less than 7.34% at all SNPs. These null results
for SNPs 5, 175, 219, and 222 reﬂect the extra information
available to the Bayesian model through studies that have
typed SNPs in high LDwith 5, 175, 219, and 222, but not 5,
175, 219, and 222 themselves: absence of evidence for
association in these studies makes association at 5, 175,
219, and 222 less likely.
The posterior probabilities of the null model in each
block were 87.9%, 90.0%, and 81.6%, which, in compar-
ison to a prior probability of 90.5% from the truncated
Poisson prior described above, result in Bayes Factors
against the null model of 1.3, 1.1, and 2.1, respectively.
For all three blocks, we checked convergence by visuallyTable 7. Average Results from Bayesian Multi-SNP Meta-Analyses of Simulated Data Replicates
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5 sHap
Number of studies 7 4 13 1 7 –
True OR 1 1.5a 1 1 1 –
Mean posterior probability (SE) 0.02(0.03) – 0.23(0.22) 0.81(0.21) 0.02(0.04) 1.00(0)
Mean OR (SE) 1.00(<0.01) – 1.04(0.12) 1.34(0.12) 1.00(<0.01) 0.11(0.02)b
Mean BCI length 0.02 – 0.34 0.42 0.02 0.10
Mean OR present (SE)c 0.98(0.06) – 1.19(0.25) 1.39(0.03) 0.96(0.05) 0.11(0.02)b
Mean BCI length presentc 0.18 – 0.56 0.29 0.16 0.10
Results are means (SE) of estimators over 20 analyses of replicate data sets simulated under identical conditions. In each analysis, OR estimates were taken
as the median of the posterior sample.
a Deleting data on the causal SNP 2 in these replicates simulated a scenario in which the causal SNP is unobserved.
b These are point estimates of sHap and therefore are not ORs.
c Calculated on the condition that the SNP was included in a model.erican Journal of Human Genetics 84, 567–580, May 15, 2009 573
Figure 2. Study-Reported MAFs for Excluded SNPs 9 and 41
Both these SNPs were excluded from our analysis. The HapMap MAF for SNP 9 is very different from that reported by the three studies;
because only Zee et al.23 report the rs number (as rs3117), this SNP might have been misidentified. The HapMap MAF for SNP 41 is substan-
tially different from the average reported value, suggesting that HapMap provides a poor estimate. A binomial normal approximation was
used for calculating 95% CIs. SNPs are indicated by their deCODE numbers.inspecting posterior plots and by running additional
chains starting in the saturated model. Sensitivity to
model-space prior was checked by changing the truncated
Poisson mean to 0.05 and 0.2. Inference was similar in all
these additional analyses (results not shown).
For block 2, sensitivity was further checked by excluding
the Meschia,24 Staton25, and Gretarsdottir8 data, one study
at a time. Meschia was excluded because of the outlying
MAF reported for SNP 42 and Staton and Gretarsdottir
Figure 3. Pairwise LD between All 23 SNPs Analyzed
Estimates are based on HapMap data. SNPs are indicated by their
deCODE numbers. Based on the r2 pairwise LD measure.574 The American Journal of Human Genetics 84, 567–580, May 15because they explainmost of the heterogeneity in reported
ORs in this block. To explore small-study bias, we also ran
an analysis with the ﬁve largest studies (those with > 500
cases) only. Again, inference was the same in all these addi-
tional analyses (Table S5). The consistently null result
when the Gretarsdottir8 data were excluded is notable
because exclusion of these data from univariate analysis
results in a borderline signiﬁcant OR at SNP 42 of 1.19.
95% CI: (1.02,1.39).
These further sensitivity analyses were not carried out
for blocks 1 and 3 because there was no signiﬁcant hetero-
geneity in reported effect estimates within these blocks,
and too few studies contributed data to allow small-study
bias to be explored (ﬁve and three studies for blocks 1
and 3, respectively).
Figures 4 and5provide two recommendeddiagnostics for
our model. Figure 4 shows a forest plot of the estimated
MAFs for SNP 45 (the SNP with most prior interest); these
estimates were obtained from application of our model to
block 2. Note that SNP 45 was not typed in Woo,26 so this
estimate has been imputed on the basis of MAFs observed
at other SNPs in close LD. Reassuringly, among studies
that did type SNP 45, our model estimates are similar to
reported estimates. Figure 5 shows a forest plot of study-
speciﬁc effect estimates for SNP 45, again from application
of our model to block 2. Model selection was turned off
for this analysis, and the model was ﬁxed with just SNP 45
present. A shrinkage prior, with 90.5% prior probabiltiy of
no effect, enabled comparison with the above reversible
jump analyses. Note that although restricting this analysis
allowedaneffect at SNP45alone, theanalysis still combines, 2009
Table 8. Single-SNP Analysis of PDE4D/Stroke Data on SNPs 2–37, or Block 1
SNP 2 SNP 3 SNP 5 SNP 13 SNP 14 SNP 15
Number of studies 1 1 1 1 1 1
ORa 1.02 1.00 0.90 1.00 0.96 0.94
95% CI (0.88,1.17) (0.87,1.16) (0.78,1.04) (0.87,1.15) (0.83,1.11) (0.82,1.08)
SNP 19 SNP 22 SNP 26 SNP 34 SNP 35 SNP 37
Number of studies 1 1 5 4 1 1
ORa 1.12 0.94 1.02 0.99 0.98 0.91
95% CI (0.95,1.31) (0.81,1.09) (0.93,1.12) (0.91,1.08) (0.86,1.13) (0.78,1.06)
a Estimates obtained via the Mantel-Haenszel technique when the SNP was typed in just one study or from a random-effects meta-analysis when the SNP
was typed in more than one study.evidence across all SNPs in block 2. Again, except for the
imputed value forWoo, effect estimates are similar to those
reported elsewhere. The global OR estimate was 1 95.5% of
the time, conﬁrming that although in isolationmany study
estimates are consistent with a sizeable effect, when infor-
mation is combined across studies CIs become tighter
around an OR of 1.
Discussion
Literature-based meta-analysis provides an important tool
for the identiﬁcation and characterization of genetic asso-
ciations, but to date it has been restricted to single-SNP
analyses. This is inefﬁcient because only studies that
have typed the particular SNP may be used, despite
substantial variation in SNP sets between studies. Further-
more, single-SNP analysis is vulnerable to between-marker
confounding, which hinders the identiﬁcation of causal
SNPs and can reduce power, as shown in our simulation
results. We present a multimarker approach that allows
simultaneous analysis of all SNPs and studies and thus
maximizes the power to ﬁnd gene-disease associations
and for each SNP obtains effect estimates, adjusted for
other SNPs. To form adjusted effect estimates, and allow
sharing of information between correlated SNPs, we used
HapMap data in the current analysis. Other sources of
information on haplotype frequencies could be incorpo-
rated: in particular, when individual patient data (IPD)
are available from one or more study, it could be incorpo-
rated to make likelihood contributions as haplotype
frequency estimates. Inference is made in the Bayesian
framework, via a reversible jump MCMC algorithm that
allows calculation of the posterior probability that anyThe AmSNP or set of SNPs is associated with disease, as well as esti-
mation of effect size for any such set of SNPs. In particular,
this allows a test of association at the gene level, which
increases power and reduces the difﬁculty of interpreting
multiple individual SNP results.
Our new method has enabled us to perform the most
thorough meta-analysis to date of the association between
PDE4D and stroke, and on the basis of these results, it
seems likely that the association is null, or too small to
be of clinical relevance. Our results overall were consistent
with those from Bevan10: the power increase obtained
through the use of our newly developed methods did not
uncover any previously unidentiﬁed genetic associations.
The evidence to date does not support PDE4D as a potential
drug target for the prevention or treatment of stroke.
However, we cannot exclude the possibility that causal
variants not well tagged by the SNPs studied here exist.
Under r2 thresholds of 0.7 and 0.8, the SNPs we analyze
tag only 11% and 8% of the 1,542 SNPs typed in
HapMap between the two most widely separated SNPs
considered by Gretarsdottir.8 Our results—and indeed, all
previous analyses of the association between PDE4D and
stroke—therefore largely rely on Gretarsdottir et al.’s orig-
inal identiﬁcation of SNPs that accurately tag any causal
variants in PDE4D. Despite the intense interest in this
gene over the last 5 years, there might exist causal variants
that are not well tagged, or that because of type II error are
not associated with stroke in Gretarsdottir et al.. It is hoped
that large whole-genome association studies currently in
progress will resolve this issue in the near future.
Our model assumes that both LD structure and any
gene-disease associations are similar across the individual
studies. It is difﬁcult to be certain that either of these
assumptions is true, but diagnostics (see forest plots ofTable 9. Single-SNP Analysis of PDE4D/Stroke Data on SNPs 39–89, or Block 2
SNP 39 SNP 42 SNP 45 SNP 83 SNP 87 SNP 89
Number of studies 1 4 13 7 6 5
ORa 0.97 1.05 1.01 1.01 0.99 1.05
95% CI (0.60,1.57) (0.82,1.36) (0.91,1.13) (0.86,1.17) (0.89,1.1) (0.81,1.37)
a Estimates obtained via the Mantel-Haenszel technique when the SNP was typed in just one study or from a random-effects meta-analysis when the SNP
was typed in more than one study.erican Journal of Human Genetics 84, 567–580, May 15, 2009 575
Table 10. Single-SNP Analysis of PDE4D/Stroke Data on SNPs 175–222, or Block 3
SNP 175 SNP 199 SNP 219 SNP 220 SNP 222
Number of studies 2 2 1 2 3
ORa 0.90 0.97 1.25 1.04 0.91
95% CI (0.79,1.02) (0.85,1.1) (0.97,1.6) (0.82,1.31) (0.82,1.02)
a Estimates from random-effects meta-analyses.control MAFs in Figures S2 and S3) provide no evidence
that they are not. In particular MAFs in controls seem to
be very consistent across the studies, and our estimate of
the random-effects variance in control haplotype frequen-
cies suggests little heterogeneity. Similarly, for most SNPs,
we have found no evidence for study heterogeneity in
effect. Where there was weak evidence of heterogeneity
of study effects, notably for SNP 42, where one estimate
of effect was in the opposite direction of estimates from
the other three studies attempting to type it, our model
proved more robust to this heterogeneity than single-locus
analysis: exclusion of the outlying study resulted in
a signiﬁcant association in the frequentist (classical) anal-
ysis, but a null result in the Bayesian analysis, compatible
with the analysis if all studies. This robustness is to be ex-
pected because our approach borrows information from
SNPs in LD with SNP 42, and these data are inconsistent
with an effect at SNP 42, regardless of the inclusion of
the outlying study.
As we have shown in our simulation studies, ourmethod
is susceptible to confounding when the causal site is unob-
served; however, in contrast to single-SNP analysis, our
method was still able to correct for confounding at two
of the four noncausal loci. Furthermore, in this scenario
the ability of our method to provide inference about the
number of causal sites is potentially valuable, although
care must be taken if multiple causal sites are inferred
because this may simply be an indication that a single
causal site needs multiple markers to tag it. Finally, we
note that our model is only intended for use with candi-date genes, where the number of SNPs analyzed will be
limited to the tens. Performance when our model is
applied to more SNPs will depend on the sparseness of
the data and the amount of prior information available
on haplotype frequencies.
In summary, we have developed a novel Bayesian
approach to the meta-analysis of genetic-association
studies and applied this to provide the most conclusive
evidence to date that there is no effect of PDE4D on stroke.
We expect the method to be of wide applicability, given
the increasing interest in meta-analysis of genetic-associa-
tion studies. Our method is released as a cross-platform
Java program under the GPL and is available for download
from our website (see Web Resources).
Appendix A
For M markers with H underlying haplotypes, we deﬁne
a multivariate normal approximation for observed log-
allele counts, denoted by log(q) ¼ (log(q1), ..log(qM))’,
parameterized by the ﬁrst H – 1 unobserved haplotype
probabilities, denoted by p½H ¼ ðp1,::pH1Þ0 and the
sample size n. Let p[H] be the (unobserved) haplotype rela-
tive frequencies in the sample. In order to use themultivar-
iate delta method to derive an approximate distribution of
log(q), we need to deﬁne a mapping (and its derivative),
g : p½H,n/logðqÞ. The Material and Methods section
presents a mapping from the unobserved sample haplo-
type counts, h[H], to the log allele counts; (2). By
substituting h[H] ¼ 2np[H], we obtainTable 11. Bayesian Multi-SNP Analysis of PDE4D/Stroke Data on SNPs 2–37, or Block 1
SNP 2 SNP 3 SNP 5 SNP 13 SNP 14 SNP 15
Posterior probability 0.01 0.03 0.03 0.01 0.01 0.01
OR 1.00 1.00 1.00 1.00 1.00 1.00
BCI (1.00,1.00) (1.00,1.00) (0.98,1.00) (1.00,1.00) (1.00,1.00) (1.00,1.00)
OR presb 0.99 1.46 0.80 1.02 1.01 0.97
BCI presb (0.93,1.08) (0.95,2.07) (0.48,1.03) (0.94,1.05) (0.94,1.05) (0.88,1.05)
SNP 19 SNP 22 SNP 26 SNP 34 SNP 35 SNP 37 sHap
Posterior probability 0.01 0.02 0.01 0.01 0.01 0.01 1.00
OR 1.00 1.00 1.00 1.00 1.00 1.00 0.07a
BCI (1.00,1.00) (1.00,1.00) (1.00,1.00) (1.00,1.00) (1.00,1.00) (1.00,1.00) (0.03,0.2)
OR presb 0.99 0.95 1.00 0.98 0.99 0.95 0.07a
BCI presb (0.92,1.08) (0.49,1.09) (0.91,1.05) (0.89,1.04) (0.92,1.09) (0.81,1.03) (0.03,0.20)
Point estimates of each parameter were taken as the median of the corresponding posterior sample.
a These are point estimates of sHap and therefore are not ORs.
b Calculated on the condition that the SNP was included in a model.
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Table 12. Bayesian Multi-SNP Analysis of PDE4D/Stroke Data on SNPs 39–89, or Block 2
SNP 39 SNP 42 SNP 45 SNP 83 SNP 87 SNP 89 sHap
Posterior probability 0.02 0.04 0.01 0.01 0.01 0.01 1.00
OR 1.00 1.00 1.00 1.00 1.00 1.00 0.38a
BCI (1.00,1.00) (1.00,1.05) (1.00,1.00) (1.00,1.00) (1.00,1.00) (1.00,1.00) (0.28,0.52)
OR presb 1.04 1.07 1.04 1.03 0.97 1.01 0.38a
BCI presb (0.98,1.10) (1.00,1.14) (0.96,1.1) (0.97,1.08) (0.93,1.02) (0.94,1.08) (0.28,0.52)
Point estimates of each parameter were taken as the median of the corresponding posterior sample.
a These are point estimates of sHap and therefore are not ORs.
b Calculated on the condition that the SNP was included in a model.logðqÞ ¼ g
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where design matricesD andX are deﬁned in the methods
section, andD[, H] denotes theHth column ofD. The deriv-
ative of g, required for the multivariate delta method
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The multivariate delta method15 provides an approxi-
mate MVN distribution for a vector function, g, of p[H]
and n.
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ðA4Þwhere Sðp½HÞ denotes the multinomial covariance matrix
of these ﬁrst H – 1 probabilities. Therefore, substituting
Equation (A2) into Equation (A4), we obtain the following
MVN for logðqÞjp½H,n
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Appendix B
Moves Within the Model Space
As described in the Material and Methods, the model was
ﬁtted via a reversible jump MCMC algorithm, which
enabled model selection. Whether it was necessary to
include study-speciﬁc haplotype frequencies and all H
haplotypes in the model was not part of the main study
question, so it was decided that the study-speciﬁc haplo-
type frequencies and between-study variance parameter
would always remain in the model. The question being
investigated was whether each SNP has an association
with disease, so the set of models between which the
reversible jump algorithm was allowed to move was
deﬁned by all possible combinations of OR parameters
being included or excluded for each marker. Therefore, if
M markers are considered for analysis, there will be a set
of
Pm¼M
m¼0

M
m

possible models that reversible jump may
move between.
Determining the probability of a model move was a two-
stage process. First, the type of move was determined fromTable 13. Bayesian Multi-SNP Analysis of PDE4D/Stroke Data on SNPs 175–222, or Block 3
SNP 175 SNP 199 SNP 219 SNP 220 SNP 222 sHap
Posterior probability 0.06 0.02 0.04 0.02 0.07 1.00
OR 1.00 1.00 1.00 1.00 1.00 0.21a
BCI (0.88,1.00) (1.00,1.00) (1.00,1.06) (1.00,1.00) (0.85,1.00) (0.08,0.64)
OR presb 0.89 0.99 1.15 1.05 0.88 0.21a
BCI presb (0.80,1.00) (0.88,1.11) (0.92,1.69) (0.87,1.28) (0.66,1.00) (0.08,0.64)
Point estimates of each parameter were taken as the median of the corresponding posterior sample.
a These are point estimates of sHap and therefore are not ORs.
b Calculated on the condition that the SNP was included in a model.
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four possibilities: adding a marker OR, removing a marker
OR, swapping the OR of onemarker for another, or making
a ‘‘null’’ move where no change occurs. An addition can
only occur when there are <M ORs present, a removal
can only occur when there are >0 ORs present, and
a swap can only occur when there are >1 ORs present.
Swap, addition, and removal moves were each given a 16
probability of happening, when such a move was avail-
able. The null move therefore had a 12 chance of happening
when all other move types were available, although this
was increased by the probabilities assigned to other move
types when they were unavailable.
Second, if an addition, removal, or swap move was
selected, themarkers tobe involved in themovewerepicked
from the markers available for the move (e.g., an addition
can only involve markers with ORs currently excluded)
with equal probability. Therefore, one determines the prob-
ability of a particular model move within the model space
by multiplying the probability of the move type and, with
the exception of a ‘‘null’’ move, the probability of selecting
the particular marker(s) involved in the move.
Parameter Updates
We adopt a proposal mechanism that updates one param-
eter type at each iteration of the reversible jump algorithm.
Figure 4. Bayesian Multilocus Analysis: Study-Specific MAF
Estimates for SNP 45
These were estimated from application of our model to data on
SNPs 39–89. Woo et al.26 did not type SNP 45,(26), so this estimate
was imputed by our model. For each MAF, 95% credible intervals
are given.578 The American Journal of Human Genetics 84, 567–580, May 15For each proposal made in the reversible jump algorithm,
there are four types of parameters that may be updated:
d Study-speciﬁc control haplotype probabilities ps0
d Grand mean control haplotype probabilities p0
d Between-study haplotype standard error sHap
d SNP log-ORs b.
The parameter type to update is chosen at random, with
weighting equal to thenumberof occurrences of theparam-
eter type in the model under consideration. Note that the
variance parameters for all proposal distributions below
are tuned toobtain anacceptance rate of approximately 0.4.
Updating Control Haplotype Probabilities ps0 and p0
For modeling the hierarchical relationship of the study-
speciﬁc haplotype probabilities at each iteration for each
study, parameters gs ¼ (gs1, ..gsH) are stored. These deﬁne
study-speciﬁc haplotype probabilities via the following
multinomial-logit link;
ps0,h ¼
exp

gsh

P
i¼1,::H
exp

gsi
 for h ¼ 1,::H and s ¼ 1,::S (B1)
Figure 5. Bayesian Multilocus Analysis: Study-specific OR
Estimates for SNP 45
These were estimated from application of our model to data on
SNPs 39–89. The posterior probability for a global effect of SNP
45 on stroke was 5%, suggesting that although data from several
studies are consistent with considerable effects, when data are
pooled, any effect disappears. The global effect is omitted from
the plot because the low posterior probability meant no reliable
estimate was obtained. Woo et al. did not type SNP 4526, so this
estimate was imputed by our model. For each OR, 95% credible
intervals are given., 2009
When a study-speciﬁc vector of haplotype probabilities,
ps0, is selected to be updated, an element of the correspond-
ing gs is chosen at random, and a new value is drawn from
a normal distribution centered on the current value,
leading to gs*. Applying Equation (B1) to gs* results in
a new set of haplotype probabilities ps

0 . Note that
although gs and gs* only differ by one element, each
element of ps0 and p
s
0 differs. The advantage of updating
in this way is that the elements of ps

0 are always between
0 and 1 and sum to 1. Grand mean haplotype probabilities
are updated in the same way.
Updating Between-Study Haplotype Frequency
Variance, sHap
Because this parameter must always be positive, it is up-
dated on the log scale. This is also achieved via a normal
distribution centered on the current (log) value.
Updating SNP Log-OR b Values
These are updated using a normal distribution centered on
the current value.
Supplemental Data
Supplemental Data include four ﬁgures and ﬁve tables and can be
found with this article online at http://www.ajhg.org/.
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Web Resources
The URLs for data presented herein are as follows:
HapMap homepage, http://www.hapmap.org/
Java code, http://homepages.lshtm.ac.uk/~encdpnew/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim
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